Evaluating Vaccines against Ebola

• Research type

  Research Study

• Full title

  A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults.

• IRAS ID

  169493

• Contact name

  Matthew Snape

• Contact email

  matthew.snape@paediatrics.ox.ac.uk

• Sponsor organisation

  Crucell Holland B.V.

• Eudract number

  2014-004883-89

• Duration of Study in the UK

  1 years, 2 months, 9 days

• Research summary

  This is a first-in-human study looking at the safety and tolerability of two candidate vaccines against Ebola (Ad26.ZEBOV and MVA-BN®-Filo) when given by intramuscular injection to healthy adult volunteers. These vaccines will be given as part of an immunisation schedule according to a 'prime-boost' approach, i.e. participants will receive one vaccine followed 1 to 2 months later by the other. Different arms of the study will receive the vaccines in different order.
  Immune responses to the vaccine schedules will also be assessed.

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  14/SC/1408

• Date of REC Opinion

  11 Dec 2014

• REC opinion

  Further Information Favourable Opinion